|
1
|
Zeng X, Li J, Peng L, Wang Y, Tan C, Chen
G, Wan X, Lu Q and Yi L: Economic outcomes of maintenance gefitinib
for locally advanced/metastatic non-small-cell lung cancer with
unknown EGFR mutations: A semi-Markov model analysis. PLoS One.
9:e888812014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rosen LS, Gordon D, Tchekmedyian NS,
Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng
M, Urbanowitz G, et al: Long-term efficacy and safety of zoledronic
acid in the treatment of skeletal metastases in patients with
nonsmall cell lung carcinoma and other solid tumors: A randomized,
Phase III, double-blind, placebo-controlled trial. Cancer.
100:2613–2621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
He YF, Luo HQ, Wang W, Chen J, Yao YW, Cai
SB, He J, Yan Y, Wu SS, Hu XX, et al: Clinical features and
prognosis-associated factors of non-small cell lung cancer
exhibiting symptoms of bone metastasis at the time of diagnosis.
Oncol Lett. 9:2706–2712. 2015.PubMed/NCBI
|
|
4
|
Ulas A, Bilici A, Durnali A, Tokluoglu S,
Akinci S, Silay K, Oksuzoglu B and Alkis N: Risk factors for
skeletal-related events (SREs) and factors affecting SRE-free
survival for nonsmall cell lung cancer patients with bone
metastases. Tumour Biol. 37:1131–1140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Santini D, Barni S, Intagliata S, Falcone
A, Ferraù F, Galetta D, Moscetti L, La Verde N, Ibrahim T, Petrelli
F, et al: Natural history of non-small-cell lung cancer with bone
metastases. Sci Rep. 5:186702015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shimada H, Setoguchi T, Yokouchi M, Sasaki
H, Ishidou Y, Kawamura I, Abematsu M, Nagano S and Komiya S:
Metastatic bone tumors: Analysis of factors affecting prognosis and
efficacy of CT and F-FDG PET-CT in identifying primary lesions. Mol
Clin Oncol. 2:875–881. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mirels H: Metastatic disease in long
bones. A proposed scoring system for diagnosing impending
pathologic fractures. 1989. Clin Orthop Relat Res. (415
Suppl):S4–S13. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu M, Zhao J, Song SW, Zhuo M, Wang X, Bai
H, Wang S, Yang L, An T, Zhang Y, et al: EGFR mutations are
associated with prognosis but not with the response to front-line
chemotherapy in the Chinese patients with advanced non-small cell
lung cancer. Lung Cancer. 67:343–347. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aggarwal C and Langer CJ: Older age, poor
performance status and major comorbidities: How to treat high-risk
patients with advanced nonsmall cell lung cancer. Curr Opin Oncol.
24:130–136. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leprieur Giroux E, Lavole A, Ruppert AM,
Gounant V, Wislez M, Cadranel J and Milleron B: Factors associated
with long-term survival of patients with advanced non-small cell
lung cancer. Respirology. 17:134–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kalikaki A, Koutsopoulos A, Hatzidaki D,
Trypaki M, Kontopodis E, Stathopoulos E, Mavroudis D, Georgoulias V
and Voutsina A: Clinical outcome of patients with non-small cell
lung cancer receiving front-line chemotherapy according to EGFR and
K-RAS mutation status. Lung Cancer. 69:110–115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Leung EY, Scott HR and McMillan DC:
Clinical utility of the pretreatment glasgow prognostic score in
patients with advanced inoperable non-small cell lung cancer. J
Thorac Oncol. 7:655–662. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pirker R, Pereira JR, Szczesna A, von
Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Eberhardt
WE, de Marinis F, et al: Prognostic factors in patients with
advanced non-small cell lung cancer: Data from the phase III FLEX
study. Lung Cancer. 77:376–382. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Jin B, Shao M, Dong Y, Lou Y,
Huang A and Han B: Monitoring of carcinoembryonic antigen levels is
predictive of EGFR mutations and efficacy of EGFR-TKI in patients
with lung adenocarcinoma. Tumour Biol. 35:4921–4928. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Duan JC, An TT, Wu MN, Yang L, Bai H, Wang
ZJ, Wang YY, Zhuo ML, Zhao J, Wang SH and Wang J: Correlation
between the efficacy of epidermal growth factor receptor tyrosine
kinase inhibitors and EGFR mutations in advanced squamous cell lung
cancer. Zhonghua Jie He He Hu Xi Za Zhi. 35:323–328. 2012.(In
Chinese). PubMed/NCBI
|
|
17
|
Stetler-Stevenson WG: Type IV collagenases
in tumor invasion and metastasis. Cancer Metastasis Rev. 9:289–303.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mundy GR: Mechanisms of bone metastasis.
Cancer. 80 (8 Suppl):S1546–S1556. 1997. View Article : Google Scholar
|
|
19
|
Tomita A, Kasaoka T, Inui T, Toyoshima M,
Nishiyama H, Saiki H, Iguchi H and Nakajima M: Human breast
adenocarcinoma (MDA-231) and human lung squamous cell carcinoma
(Hara) do not have the ability to cause bone resorption by
themselves during the establishment of bone metastasis. Clin Exp
Metastasis. 25:437–444. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Coleman RE: Metastatic bone disease:
Clinical features, pathophysiology and treatment strategies. Cancer
Treat Rev. 27:165–176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Coleman RE: Bisphosphonates: Clinical
experience. Oncologist. 9 Suppl 4:S14–S27. 2004. View Article : Google Scholar
|
|
22
|
Cetin K, Christiansen CF, Jacobsen JB,
Nørgaard M and Sørensen HT: Bone metastasis, skeletal-related
events, and mortality in lung cancer patients: A Danish
population-based cohort study. Lung Cancer. 86:247–254. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bae HM, Lee SH, Kim TM, Kim DW, Yang SC,
Wu HG, Kim YW and Heo DS: Prognostic factors for non-small cell
lung cancer with bone metastasis at the time of diagnosis. Lung
Cancer. 77:572–577. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Plones T, Osei-Agyemang T, Krohn A and
Passlick B: Surgical treatment of extrapulmonary oligometastatic
non-small cell lung cancer. Indian J Surg. 77 Suppl 2:S216–S220.
2015. View Article : Google Scholar
|
|
25
|
Chen YJ, Chang GC, Chen HT, Yang TY, Kuo
BI, Hsu HC, Yang HW and Lee TS: Surgical results of metastatic
spinal cord compression secondary to non-small cell lung cancer.
Spine (Phila Pa 1976). 32:E413–E418. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lei M, Liu Y, Tang C, Yang S, Liu S and
Zhou S: Prediction of survival prognosis after surgery in patients
with symptomatic metastatic spinal cord compression from non-small
cell lung cancer. BMC Cancer. 15:8532015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Niu FY, Zhou Q, Yang JJ, Zhong WZ, Chen
ZH, Deng W, He YY, Chen HJ, Zeng Z, Ke EE, et al: Distribution and
prognosis of uncommon metastases from non-small cell lung cancer.
BMC Cancer. 16:1492016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Urschel JD, Finley RK and Takita H:
Long-term survival after bilateral adrenalectomy for metastatic
lung cancer: A case report. Chest. 112:848–850. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Karolyi P: Do adrenal metastases from lung
cancer develop by lymphogenous or hematogenous route? J Surg Oncol.
43:154–156. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chadeyras JB, Mazel C and Grunenwald D:
Vertebral en bloc resection for lung cancer: Twelve years'
experience. Ann Chir. 131:616–622. 2006.(In French). View Article : Google Scholar : PubMed/NCBI
|
